Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $109.25 Consensus Target Price from Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has received a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, thirteen have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $109.25.

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 target price on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Finally, Citizens Jmp cut their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th.

Structure Therapeutics Trading Up 1.6%

GPCR stock opened at $40.17 on Friday. The company has a market cap of $2.85 billion, a P/E ratio of -46.17 and a beta of -1.31. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90. The company’s 50-day moving average price is $45.51 and its 200 day moving average price is $57.00.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, equities research analysts expect that Structure Therapeutics will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aberdeen Group plc raised its position in shares of Structure Therapeutics by 46.1% in the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after buying an additional 185,245 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of Structure Therapeutics in the third quarter valued at approximately $4,770,000. Private Capital Advisors Inc. acquired a new position in shares of Structure Therapeutics in the third quarter valued at approximately $1,545,000. Capricorn Fund Managers Ltd acquired a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $17,568,000. Finally, First Light Asset Management LLC raised its position in shares of Structure Therapeutics by 61.5% in the third quarter. First Light Asset Management LLC now owns 197,350 shares of the company’s stock valued at $5,526,000 after buying an additional 75,124 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.